TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37244365

Group type: EXPERIMENTAL
Intervention: Hatha yoga group
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Aerobic exercise group
Number of subjects: 168

Group type: COMPARATOR
Intervention: Stretching-toning active control group
Number of subjects: 168
Study: 37244367

Group type: EXPERIMENTAL
Intervention: Brief clinician-administered Skills Training in Affective and Interpersonal Regulation (Brief STAIR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: web-administered STAIR (webSTAIR)
Number of subjects: 0
Study: 37244454

Group type: EXPERIMENTAL
Intervention: Intravaginal estrogen (1 g conjugated estrogen intravaginal cream, 0.625 mg/g)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 37244458

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Abdominal myomectomy
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Number of subjects: 1384
Study: 37244626

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost
Number of subjects: 502

Group type: COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy with Sequential Boost
Number of subjects: 502
Study: 37244810

Group type: EXPERIMENTAL
Intervention: Tdap immunization in pregnant women
Number of subjects: 81
Study: 37244942

Group type: EXPERIMENTAL
Intervention: Mobilized peripheral blood-derived hematopoietic stem/progenitor cells
Number of subjects: 13

Group type: COMPARATOR
Intervention: Bone marrow-derived hematopoietic stem/progenitor cells
Number of subjects: 13
Study: 37245012

Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) performed under cone beam CT guidance (CBCT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Electromagnetic navigation bronchoscopy (ENB) performed in a classical endoscopy suite
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Trans-bronchial lung cryobiopsy (TBLC) in addition to trans-bronchial biopsies (TBB)
Number of subjects: 49
Study: 37245018

Group type: EXPERIMENTAL
Intervention: Music therapy (individual and group) in addition to standard treatment for 10 participants (6 weekly sessions)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard treatment only for 5 participants (control group)
Number of subjects: 15
Study: 37245030

Group type: EXPERIMENTAL
Intervention: Hyperhydration (200% maintenance balanced crystalloid fluids up to targets of 10% weight gain and 20% reduction in hematocrit)
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Conservative fluid management (in- or outpatients based on clinician preference, focused on close laboratory monitoring and maintenance of euvolemia)
Number of subjects: 1040
Study: 37245041

Group type: EXPERIMENTAL
Intervention: Peer-facilitated telemedicine HCV care (peer tele-HCV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 0
Study: 37245042

Group type: EXPERIMENTAL
Intervention: Screening algorithm based on primary care EHR data
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (58,223 patients)
Number of subjects: 30
Study: 37245191

Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (IL2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37245250

Group type: EXPERIMENTAL
Intervention: Carvedilol therapy
Number of subjects: 794

Group type: COMPARATOR
Intervention: No β-blocker therapy
Number of subjects: 794
Study: 37245331

Group type: EXPERIMENTAL
Intervention: High-fat/high-sugar diet (HFHS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-fat/low-sugar diet
Number of subjects: 15
Study: 37245522

Group type: EXPERIMENTAL
Intervention: CPX-351 (intravenous, 100 mg/m²)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 31
Study: 37245517

Group type: EXPERIMENTAL
Intervention: Care bundle intervention including early intensive lowering of systolic blood pressure (target <140 mm Hg), strict glucose control (target 6·1-7·8 mmol/L for non-diabetics and 7·8-10·0 mmol/L for diabetics), antipyrexia treatment (target body temperature ≤37·5°C), and rapid reversal of warfarin-related anticoagulation (target INR <1·5) within 1 hour of treatment.
Number of subjects: 7036

Group type: COMPARATOR
Intervention: Usual care group (control).
Number of subjects: 7036
Study: 37245660

Group type: EXPERIMENTAL
Intervention: Fat density biomarker (calibrated fat intake)
Number of subjects: 81954

Group type: COMPARATOR
Intervention: Fat density biomarker (calibrated fat intake) with control for additional dietary variables
Number of subjects: 81954
Study: 37245855

Group type: EXPERIMENTAL
Intervention: Treatment Effectiveness Assessment (TEA)
Number of subjects: 403
Study: 37245989

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (approved dose)
Number of subjects: 2540
Study: 37246231

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 45
Study: 37246242

Group type: EXPERIMENTAL
Intervention: Self-warming (SW) blanket
Number of subjects: 150

Group type: COMPARATOR
Intervention: Forced-air warming (FAW) blanket
Number of subjects: 150
Study: 37246259

Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control (no LAIV)
Number of subjects: 320
Study: 37246308

Group type: EXPERIMENTAL
Intervention: Sexual counseling with the PLISSIT model for 12 weeks after surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine postoperative care (control group)
Number of subjects: 70
Study: 37246339

Group type: EXPERIMENTAL
Intervention: Care quality assessment for Black participants
Number of subjects: 701

Group type: COMPARATOR
Intervention: Care quality assessment for White participants
Number of subjects: 701
Study: 37246348

Group type: EXPERIMENTAL
Intervention: Blinatumomab treatment
Number of subjects: 70
Study: 37246588

Group type: EXPERIMENTAL
Intervention: Dasatinib discontinuation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Dasatinib re-initiation after relapse
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Off-treatment period
Number of subjects: 84
Study: 37246632

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) risk report
Number of subjects: 25000
Study: 37246798

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study: 37246953

Group type: EXPERIMENTAL
Intervention: Sutimlimab
Number of subjects: 22
Study: 37246998

Group type: EXPERIMENTAL
Intervention: NY104 PET tracer
Number of subjects: 3
Study: 37247007

Group type: EXPERIMENTAL
Intervention: Rural patients
Number of subjects: 36482
Study: 37247089

Group type: EXPERIMENTAL
Intervention: Average Facebow Group (AFG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Professional Facial Scan Group (PFG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Smartphone Facial Scan Group (SFG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cone-Beam Computed Tomography Group (CTG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Average Mounting Group (AMG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Kinematic Facebow Group (KFG)
Number of subjects: 14
Study: 37247166

Group type: EXPERIMENTAL
Intervention: SCT510 (3 mg/kg infusion)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bevacizumab (Avastin, 3 mg/kg infusion)
Number of subjects: 84
Study: 37247190

Group type: EXPERIMENTAL
Intervention: Voxelotor 1500 mg daily
Number of subjects: 10
Study: 37247226

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 2584

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 2584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2584
Study: 37247819

Group type: EXPERIMENTAL
Intervention: Carotenoid group (10 mg L and 2 mg Z softgel)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (placebo softgel)
Number of subjects: 47
Study: 37247850

Group type: EXPERIMENTAL
Intervention: Active arm: animation including brief alcohol intervention (four minutes) and lifestyle health promotion (three minutes)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Control arm: lifestyle health promotion only
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Active arm
Number of subjects: 557

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 557
Study: 37247876

Group type: EXPERIMENTAL
Intervention: rhTNK-tPA 0.25 mg/kg (single bolus) to a maximum of 25 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: standard medical therapy
Number of subjects: 100
Study: 37247940

Group type: EXPERIMENTAL
Intervention: Supplemental 16 min brachytherapy educational video (Arm B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard informed consent (Arm A)
Number of subjects: 80
Study: 37247957

Group type: EXPERIMENTAL
Intervention: 40 mg oral prednisone daily for five consecutive days
Number of subjects: 456

Group type: COMPARATOR
Intervention: Identical-appearing placebo (control group) for five consecutive days
Number of subjects: 456
Study: 37247964

Group type: EXPERIMENTAL
Intervention: Behavioural intervention involving a visuospatial task (BI-VT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waitlist Control Group (WCG)
Number of subjects: 120
Study: 37248330

Group type: EXPERIMENTAL
Intervention: Modified alteplase formulation (0.2 mg/kg body weight)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Current alteplase formulation (0.2 mg/kg body weight)
Number of subjects: 30
Study: 37248494

Group type: EXPERIMENTAL
Intervention: IB1001
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37248499

Group type: EXPERIMENTAL
Intervention: Hafnia alvei HA4597™ supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37248650

Group type: EXPERIMENTAL
Intervention: HUNT for HF risk score
Number of subjects: 36511

Group type: COMPARATOR
Intervention: Existing HF risk scores (Health Aging and Body Composition HF risk score, Framingham HF risk score, Pooled Cohort equations to Prevent HF risk score, NORRISK 2)
Number of subjects: 36511
Study: 37248808

Group type: EXPERIMENTAL
Intervention: Parent Eating Disorder Examination Questionnaire (PEDE-Q)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Eating Disorder Examination Questionnaire (EDE-Q)
Number of subjects: 355
Study: 37248912

Group type: EXPERIMENTAL
Intervention: Pamrevlumab (35-mg/kg intravenous infusions every 2 weeks for 2 years)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Number of subjects: 21
Study: 37249038

Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy
Number of subjects: 0
Study: 37249422

Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR assay
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone-based all-oral shorter regimen
Number of subjects: 497

Group type: COMPARATOR
Intervention: Injectable-containing regimen
Number of subjects: 497

Group type: COMPARATOR
Intervention: Bedaquiline-based regimen
Number of subjects: 497
Study: 37249512

Group type: EXPERIMENTAL
Intervention: YTB323 (autologous CD19-directed CAR T-cell therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tisagenlecleucel (traditional CAR T-cell therapy)
Number of subjects: 0
Study: 37249619

Group type: EXPERIMENTAL
Intervention: BBT-176
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: BBT-176 combined with cetuximab
Number of subjects: 2

Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 2
Study: 37249646

Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery (GKRS)
Number of subjects: 92
Study: 37249653

Group type: EXPERIMENTAL
Intervention: Combined multi-view ultrasound variable
Number of subjects: 3532

Group type: EXPERIMENTAL
Intervention: Single cIMT measurements
Number of subjects: 3532

Group type: EXPERIMENTAL
Intervention: Plaque presence
Number of subjects: 3532

Group type: EXPERIMENTAL
Intervention: Combined multi-view ultrasound variable in 40-year olds
Number of subjects: 3532
Study: 37249658

Group type: EXPERIMENTAL
Intervention: Hydroxycitric acid (HCA)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 37249715

Group type: EXPERIMENTAL
Intervention: Supervised Mat Pilates exercise
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 156
Study: 37249860

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination (2 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination (3 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous COVID-19 infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unvaccinated NHRs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination (2 and 3 doses)
Number of subjects: 0
Study: 37250148

Group type: EXPERIMENTAL
Intervention: Entinostat plus exemestane (oral exemestane 25 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus exemestane (oral exemestane 25 mg/day)
Number of subjects: 0
Study: 37250503

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 230

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 230
Study: 37251062

Group type: EXPERIMENTAL
Intervention: Body-centred practices (body scan and Hatha yoga)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Mind-centred practices (focused attention and open monitoring meditation)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combination of both body-centred and mind-centred practices
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Sequence of implementation (mind-centred first, then body-centred)
Number of subjects: 104
Study: 37251086

Group type: EXPERIMENTAL
Intervention: UC-former deep learning model
Number of subjects: 768
Study: 37251506

Group type: EXPERIMENTAL
Intervention: Tipping Point Program (TPP)
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Tipping Point Plus Program (TPP+)
Number of subjects: 1242

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1242
Study: 37251511

Group type: EXPERIMENTAL
Intervention: PSQI Subjective Sleep Quality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSQI Use of Sleep Medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFS
Number of subjects: 0
Study: 37251624

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 185
Study: 37251625

Group type: EXPERIMENTAL
Intervention: WeChat WeQuit program
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 2000
Study: 37251627

Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 1465
Study: 37251628

Group type: EXPERIMENTAL
Intervention: PD1-19bbz infusion
Number of subjects: 21
Study: 37251944

Group type: EXPERIMENTAL
Intervention: Apatinib combined with S-1
Number of subjects: 38
Study: 37251979

Group type: EXPERIMENTAL
Intervention: Chronos-expressing vectors (AAV2 vector)
Number of subjects: 0
Study: 37252109

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin 750 mg three times daily for 100 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 37252116

Group type: EXPERIMENTAL
Intervention: Mitral valve repair (MVR) surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CMR scan including 3D late gadolinium enhancement (LGE) imaging
Number of subjects: 20
Study: 37252256

Group type: EXPERIMENTAL
Intervention: Horyzons USA digital platform
Number of subjects: 20
Study: 37252616

Group type: EXPERIMENTAL
Intervention: ChAd63-KH vaccine
Number of subjects: 0
Study: 37252734

Group type: EXPERIMENTAL
Intervention: MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor
Number of subjects: 0
Study: 37252770

Group type: EXPERIMENTAL
Intervention: Facilitated Telemedicine
Number of subjects: 0
Study: 37252945

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Class 2 carbapenems
Number of subjects: 1032
Study: 37252983

Group type: EXPERIMENTAL
Intervention: Cocoa extract (500 mg of cocoa flavanols per day)
Number of subjects: 3562

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3562
Study: 37253044

Group type: EXPERIMENTAL
Intervention: hCG + biotin (20 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: hCG + placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: hCG + biotin
Number of subjects: 10
Study: 37253139

Group type: EXPERIMENTAL
Intervention: Segesterone Acetate and Ethinyl Estradiol Contraceptive Vaginal System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Recent Oral Contraceptive or Hormonal Contraceptive Vaginal Ring Users)
Number of subjects: 0
Study: 37253387

Group type: EXPERIMENTAL
Intervention: Endoscopic vacuum therapy (EVT)
Number of subjects: 38
Study: 37253412

Group type: EXPERIMENTAL
Intervention: Placental EPO mRNA expression in multiples cohort
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Placental EPO mRNA expression in adolescents cohort
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Placental NCOA4 mRNA expression in multiples cohort
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Placental NCOA4 mRNA expression in adolescents cohort
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Placental ERFE and EPO mRNA expression
Number of subjects: 224
Study: 37253489

Group type: EXPERIMENTAL
Intervention: NHS Health Check (NHSHC)
Number of subjects: 27888
Study: 37253491

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-immunotherapy with camrelizumab and cisplatin (75-80 mg/m2)
Number of subjects: 82
Study: 37253493

Group type: EXPERIMENTAL
Intervention: Trio whole-genome sequencing (trio WGS)
Number of subjects: 0
Study: 37253497

Group type: EXPERIMENTAL
Intervention: Conscious sedation (CS)
Number of subjects: 188

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 188
Study: 37253803

Group type: EXPERIMENTAL
Intervention: Combined therapy of basiliximab with ruxolitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37253902

Group type: EXPERIMENTAL
Intervention: SCP-based counseling intervention with goal-setting
Number of subjects: 20
Study: 37253992

Group type: EXPERIMENTAL
Intervention: Home healthcare provided by physician and nurse
Number of subjects: 95831

Group type: EXPERIMENTAL
Intervention: Higher visit frequency of HHC (> 2 times/month)
Number of subjects: 95831

Group type: EXPERIMENTAL
Intervention: Higher level of resource utilization group (RUG 4)
Number of subjects: 95831

Group type: EXPERIMENTAL
Intervention: Cirrhosis as a comorbidity
Number of subjects: 95831
Study: 37254058

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ropivacaine 0.4% + dexamethasone 4 mg, 20 mL per side at the level of surgery) plus postoperative opioid analgesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Opioid-based analgesia
Number of subjects: 30
Study: 37254149

Group type: EXPERIMENTAL
Intervention: PFB-CEUS
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: MP-MRI
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Hybrid model (PFB-CEUS + MP-MRI)
Number of subjects: 179
Study: 37254209

Group type: EXPERIMENTAL
Intervention: Combination antibiotic therapy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 169
Study: 37254217

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) by a geriatrician
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 16
Study: 37254221

Group type: EXPERIMENTAL
Intervention: mHealth exercise intervention (EXCAP)
Number of subjects: 20
Study: 37254243

Group type: EXPERIMENTAL
Intervention: Simple low-cost intervention to empower dietary salt reduction, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available.
Number of subjects: 0
Study: 37254256

Group type: EXPERIMENTAL
Intervention: SCD-directed therapies (e.g., hydroxyurea, l-glutamine, crizanlizumab, voxelotor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CKD-directed therapies (e.g., renin-angiotensin-aldosterone system blockers)
Number of subjects: 0
Study: 37254449

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37254502

Group type: EXPERIMENTAL
Intervention: Carpal tunnel release with ultrasound guidance (CTR-US)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Mini-open carpal tunnel release (mOCTR)
Number of subjects: 149
Study: 37254818

Group type: EXPERIMENTAL
Intervention: Medication review intervention (n=196)
Number of subjects: 408
Study: 37254941

Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dupilumab
Number of subjects: 0
Study: 37255163

Group type: EXPERIMENTAL
Intervention: Restrictive ventilatory defect observed in patients with TLC below the lower limit of normal (42/95 patients, 44%).
Number of subjects: 95

Group type: COMPARATOR
Intervention: Patients without reduced TLC (53 patients).
Number of subjects: 95
Study: 37255194

Group type: EXPERIMENTAL
Intervention: YK-1169 (2.5 g, 2-h infusion, every 8 hours for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefepime (2 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Avibactam (0.5 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monte Carlo simulation
Number of subjects: 0
Study: 37255247

Group type: EXPERIMENTAL
Intervention: Preconception isoprostanes (8-iso-PGF2α)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Isoprostanes at 4 weeks gestation (8-iso-PGF2α)
Number of subjects: 1228
Study: 37255277

Group type: EXPERIMENTAL
Intervention: Digital Action Plan (DAP) + Written Action Plan (WAP)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Written Action Plan (WAP)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Digital Action Plan (DAP)
Number of subjects: 247
Study: 37255689

Group type: EXPERIMENTAL
Intervention: Active intradermal acupuncture group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham intradermal acupuncture group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 120
Study: 37255691

Group type: EXPERIMENTAL
Intervention: Full interventional version of the Craving-Manager app (4 weeks, EMA + EMI)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Restricted version of the Craving-Manager app (4 weeks, only EMA)
Number of subjects: 274